Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

Possible Involvement of Complement Factor C1q in the Clearance of Extracellular Neuromelanin From the Substantia Nigra in Parkinson Disease

Depboylu, C., Schafer, M. K.-H., Arias-Carrión, Ó., Oertel, W. H., Weihe, E., & Höglinger, G. U. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31820805b9 · Cited by 91

Parkinson's disease: a major hypokinetic basal ganglia disorder

Sian, J., Gerlach, M., Youdim, M. B. H., & Riederer, P. F. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050171 · Cited by 89

Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats

Lu, X., Bing, G., & Hagg, T. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00033-6 · Cited by 89

Inhibition of microglial cell activation by cortisol

Drew, P. D., & Chavis, J. A. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00275-6 · Cited by 88

Imaging Brain Microglial Activation Using Positron Emission Tomography and Translocator Protein-Specific Radioligands

Owen, D. R., & Matthews, P. M. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387718-5.00002-x · Cited by 88

Regulator of G-Protein Signaling-10 Negatively Regulates NF-κB in Microglia and Neuroprotects Dopaminergic Neurons in Hemiparkinsonian Rats

Lee, J., Chung, J., McAlpine, F. E., & Tansey, M. G. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1002-11.2011 · Cited by 89

Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease: The therapeutic role of Nrf2 activators

Saravanan, J., & Krishnamurthy, P. T. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105014 · Cited by 90

Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective

Yi, S., Wang, L., Wang, H., Ho, M. S.-C., & Zhang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314753 · Cited by 96

Inflammation and gliosis in neurological diseases – clinical implications

Członkowska, A., & Kurkowska‐Jastrzębska, I. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.09.020 · Cited by 93

Methamphetamine-induced neurotoxicity: the road to Parkinson’s disease

Thrash, B., Kariharan, T., Ahuja, M., Suppiramaniam, V. D., & Dhanasekaran, M. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70158-6 · Cited by 88

Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations

Bohár, Z., Toldi, J., Fülöp, F., & Vécsei, L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16059772 · Cited by 89

Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease

Kokovay, E., & Cunningham, L. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.023 · Cited by 88

Comparative anti-inflammatory characterization of wild fruiting body, liquid-state fermentation, and solid-state culture of Taiwanofungus camphoratus in microglia and the mechanism of its action

Liu, D.-Z., Liang, H., Chen, C.-H., Su, C., Lee, T., Huang, C., Hou, W., Lin, S., Zhong, W., Lin, P., et al. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.03.037 · Cited by 88

CpG‐containing oligodeoxynucleotide promotes microglial cell uptake of amyloid β 1–42 peptide by up‐regulating the expression of the G‐protein‐coupled receptor mFPR2

Iribarren, P., Chen, K., Hu, J., Gong, W., Cho, E. H., Lockert, S., Uranchimeg, B., & Wang, J. M. (2005) · The FASEB Journal · doi:10.1096/fj.05-4578fje · Cited by 92

The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases

Centonze, D., Battistini, L., & Maccarrone, M. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785740018 · Cited by 86

Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson’s Disease

Huang, D., Xu, J., Wang, J., Tong, J., Bai, X., Li, H., Wang, Z., Huang, Y., Wu, Y., Yu, M., et al. (2017) · Parkinson s Disease · doi:10.1155/2017/9349487 · Cited by 89

Neuroinflammation in the pathophysiology of Parkinson’s disease and therapeutic evidence of anti-inflammatory drugs

Bassani, T. B., Vital, M. A. B. F., & Rauh, L. K. (2015) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20150057 · Cited by 78

Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson’s disease

Kip, E., & Parr‐Brownlie, L. C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101618 · Cited by 89

Chronic neuroinflammation impacts the recruitment of adult-born neurons into behaviorally relevant hippocampal networks

Bélarbi, K., Arellano, C., Ferguson, R. A., Jopson, T. D., & Rosi, S. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.07.225 · Cited by 90

LPS-induced oxidative stress and inflammatory reaction in the rat striatum

Noworyta, K., Górska, A. M., & Gołembiowska, K. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71067-3 · Cited by 89

SOD1 overexpression alters ROS production and reduces neurotoxic inflammatory signaling in microglial cells

Dimayuga, F. O., Wang, C., Clark, J. M., Dimayuga, E. R., Smith, V. D., & Bruce‐Keller, A. J. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.10.003 · Cited by 87

Methamphetamine and Parkinson's Disease

Granado, N., Ares‐Santos, S., & Moratalla, R. (2013) · Parkinson s Disease · doi:10.1155/2013/308052 · Cited by 87

Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories

Doherty, G. H. (2011) · Neuroscience Bulletin · doi:10.1007/s12264-011-1530-6 · Cited by 91

Interactions between macrophages and brain microvascular endothelial cells: role in pathogenesis of HIV-1 infection and blood-brain barrier function

Nottet, H. S. L. M. (1999) · Journal of NeuroVirology · doi:10.3109/13550289909021294 · Cited by 87

Nigral overexpression of α-synuclein in a rat Parkinson's disease model indicates alterations in the enteric nervous system and the gut microbiome

O’Donovan, S. M., Crowley, E. K., Brown, J. R. ‐., O’Sullivan, O., O’Leary, O. F., Timmons, S., Nolan, Y. M., Clarke, D. J., Hyland, N. P., Joyce, S. A., et al. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13726 · Cited by 86

Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease

Kumaran, R., & Cookson, M. R. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv236 · Cited by 86

GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson’s disease

Hoban, D. B., Howard, L., & Dowd, E. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.014 · Cited by 86

Recent Advances in the Study of Bipolar/Rod-Shaped Microglia and their Roles in Neurodegeneration

Au, N. P. B., & Ma, C. H. E. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00128 · Cited by 87

Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences

Sergi, D., Renaud, J., Simola, N., & Martinoli, M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00302 · Cited by 87

Inflammation in Alzheimer’s Disease and Molecular Genetics: Recent Update

Zhang, Z., Li, Y., Ng, C. T., & Song, Y. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0351-0 · Cited by 92

Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease

Rousseaux, M. W. C., Marcogliese, P. C., Qu, D., Hewitt, S. J., Seang, S., Kim, R. H., Slack, R. S., Schlossmacher, M. G., Lagace, D. C., Mak, T. W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205102109 · Cited by 86

Cysteine Cathepsins in Neurological Disorders

Pišlar, A. H., & Kos, J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8576-6 · Cited by 86

Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation

Moore, A. H., Bigbee, M. J., Boynton, G. E., Wakeham, C. M., Rosenheim, H. M., Staral, C. J., Morrissey, J. L., & Hund, A. K. (2010) · Pharmaceuticals · doi:10.3390/ph3061812 · Cited by 90

Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia

Kao, T.-K., Ou, Y., Lin, S., Pan, H.-C., Song, P.-J., Raung, S., Lai, C.-Y., Liao, S., Lu, H., & Chen, C. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.01.011 · Cited by 86

Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease

Cao, S., Theodore, S., & Standaert, D. G. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-42 · Cited by 92

Microglia‐specific expression of microsomal prostaglandin E2 synthase‐1 contributes to lipopolysaccharide‐induced prostaglandin E2 production

Ikeda‐Matsuo, Y., Ikegaya, Y., Matsuki, N., Uematsu, S., Akira, S., & Sasaki, Y. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03302.x · Cited by 86

Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation

McNaught, K. S. P., & Jenner, P. G. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00415-9 · Cited by 86

Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity

Cotter, R. L., Burke, W. J., Thomas, V. S., POTTER, J. F., Zheng, J., & Gendelman, H. E. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.4.416 · Cited by 86

Neuroprotection and dopamine agonists

Schapira, A. H. V. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s9 · Cited by 86

Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes

Starhof, C., Winge, K., Heegaard, N. H. H., Skogstrand, K., Friis, S., & Hejl, A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1339-6 · Cited by 87

Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF-κB signaling pathway in a mouse model of Parkinson's disease

Lv, R., Du, L., Liu, X., Zhou, F., Zhang, Z., & Zhang, L. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.030 · Cited by 86

The Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Induces Apoptosis in Mouse Nigrostriatal Glia

Serra, P. A., Sciola, L., Delogu, M. R., Spano, A., Monaco, G., MIELE, E., Rocchitta, G., Miele, M., Migheli, R., & Desole, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202099200 · Cited by 84

Prolactin Induction of Nitric Oxide Synthase in Rat C6 Glioma Cells

Raso, G. M., Meli, R., Gualillo, O., Pacilio, M., & Carlo, R. D. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732272.x · Cited by 85

Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson’s disease

Yokoyama, H., Kuroiwa, H., Yano, R., & Araki, T. (2008) · Neurological Sciences · doi:10.1007/s10072-008-0986-2 · Cited by 85

Activation of Autophagy Pathway Suppresses the Expression of iNOS, IL6 and Cell Death of LPS-Stimulated Microglia Cells

Han, H.-E., Kim, T., Son, H.-J., Park, W. J., & Han, P. (2013) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.089 · Cited by 86

Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron–glia co-cultures

Liu, B., Du, L., Kong, L., Hudson, P. M., Wilson, B. C., Chang, R. C., Abel, H. H., & Hong, J. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00057-9 · Cited by 85

PGE2 receptor EP1 renders dopaminergic neurons selectively vulnerable to low‐level oxidative stress and direct PGE2 neurotoxicity

Carrasco, E., Casper, D., & Werner, P. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21425 · Cited by 86

Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication

Tripanichkul, W., Sripanichkulchai, K., & Finkelstein, D. I. (2006) · Brain Research · doi:10.1016/j.brainres.2006.02.029 · Cited by 85

Inflammasome assembly in neurodegenerative diseases

Singh, J., Habean, M. L., & Panicker, N. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.009 · Cited by 83

Interaction of RAGE with α-synuclein fibrils mediates inflammatory response of microglia

Long, H., Zhang, S., Zeng, S., Tong, Y., Liu, J., Liu, C., & Li, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111401 · Cited by 86

An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer’s Disease

Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V. K., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 89

Substance P Exacerbates Dopaminergic Neurodegeneration through Neurokinin-1 Receptor-Independent Activation of Microglial NADPH Oxidase

Wang, Q., Chu, C., Li, Q., Chen, S., Wilson, B. C., Oyarzabal, E. A., Jiang, L., Ali, S. F., Robinson, B. L., Kim, H., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2238-14.2014 · Cited by 86

A Percentage Analysis of the Telomere Length in Parkinson's Disease Patients

Guan, J. Z., Maeda, T., Sugano, M., Oyama, J.-I., Higuchi, Y., Suzuki, T., & Makino, N. (2008) · The Journals of Gerontology Series A · doi:10.1093/gerona/63.5.467 · Cited by 84

Metabolic Syndrome: An Important Risk Factor for Parkinson’s Disease

Zhang, P., & Tian, B. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/729194 · Cited by 86

Oligodendroglial α‐synucleinopathy‐driven neuroinflammation in multiple system atrophy

Hoffmann, A., Ettle, B., Battis, K., Reiprich, S., Schlachetzki, J. C. M., Masliah, E., Wegner, M., Kuhlmann, T., Riemenschneider, M. J., & Winkler, J. (2019) · Brain Pathology · doi:10.1111/bpa.12678 · Cited by 83

Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions

Varley, J. A., Brooks, D. J., & Edison, P. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.08.105 · Cited by 85

Immunomodulation of Parkinson’s disease using Mucuna pruriens (Mp)

Nand, S., Birla, H., Zahra, W., Singh, S. S., & Singh, S. P. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.06.005 · Cited by 86

Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase‐1 and brain‐derived neurotrophic factor

Kurauchi, Y., Hisatsune, A., Isohama, Y., Mishima, S., & Katsuki, H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01833.x · Cited by 83

Microglia: its development and role as a neuropathology sensor

Ling, E., Ng, Y. K., Wu, C., & Kaur, C. (2001) · Progress in brain research · doi:10.1016/s0079-6123(01)32066-6 · Cited by 83

Regulation of caspase-3 processing by cIAP2 controls the switch between pro-inflammatory activation and cell death in microglia

Kavanagh, E. T., Rodhe, J., Burguillos, M. Á., Venero, J. L., & Joseph, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.514 · Cited by 82

COX‐2 in the neurodegenerative process of Parkinson's disease

Teismann, P. (2012) · BioFactors · doi:10.1002/biof.1035 · Cited by 85

Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease

Glaab, E., & Schneider, R. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.002 · Cited by 84

Intra-parenchymal injection of tumor necrosis factor-? and interleukin 1-? produces dopamine neuron loss in the rat

Carvey, P. M., Chen, E.-Y., Lipton, J. W., Tong, C. W., Chang, Q. A., & Ling, Z. D. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0222-z · Cited by 83

Interaction of polymorphisms in the genes encoding interleukin‐6 and estrogen receptor beta on the susceptibility to Parkinson's disease

Håkansson, A. S., Westberg, L., Nilsson, S., Buervenich, S., Belin, A. C., Holmberg, B., Sydow, O., Olson, L., Johnels, B., Eriksson, E., et al. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30136 · Cited by 83

Additive Neuroprotective Effects of Creatine and a Cyclooxygenase 2 Inhibitor Against Dopamine Depletion in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease

Klivènyi, P., Gardian, G., Calingasan, N. Y., Yang, L., & Beal, M. F. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:21:3:191 · Cited by 83

Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome

Charlett, A., Dobbs, R. J., Dobbs, S. M., Weller, C., Brady, P., & Peterson, D. W. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00654.x · Cited by 82

The Oxygen Paradox, the French Paradox, and age-related diseases

Davies, J. M. S., Cillard, J., Friguet, B., Cadenas, E., Cadet, J., Cayce, R., Fishmann, A., Liao, D., Bulteau, A.-L., Derbré, F., et al. (2017) · GeroScience · doi:10.1007/s11357-017-0002-y · Cited by 82

The small GTPase Rab11 co-localizes with -synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity

Chutna, O., Gonçalves, S. A., Villar‐Piqué, A., Guerreiro, P. S., Marijanovic, Z., Mendes, T., Ramalho, J. S., Emmanouilidou, E., Ventura, S., Klucken, J., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu391 · Cited by 82

LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease

Lee, H., James, W., & Cowley, S. A. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160262 · Cited by 88

Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice

Rocha, S. M., Bantle, C. M., Aboellail, T., Chatterjee, D., Smeyne, R. J., & Tjalkens, R. B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105685 · Cited by 87

Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: A delayed pandemic?

Serrano-Castro, P. J., Estivill‐Torrús, G., Cabezudo‐García, P., Bueno, J. A. R., Ciano-Petersen, N. L., Aguilar-Castillo, M. J., Suárez-Pérez, J., Jiménez-Hernández, M. D., Moya-Molina, M. Á., Oliver‐Martos, B., et al. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.04.002 · Cited by 82

Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not

Kreisler, A., Gelé, P., Wiart, J., Lhermitte, M., Destée, A., & Bordet, R. (2007) · Brain Research · doi:10.1016/j.brainres.2006.12.011 · Cited by 82

Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress

Qin, L., Block, M. L., Liu, Y., Bienstock, R. J., Pei, Z., Zhang, W., Wu, X., Wilson, B. C., Burka, T., & Hong, J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2857com · Cited by 81

NEW evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease

Shan, S., Hong-Min, T., Yi, F., Jun-Peng, G., Yue, F. L., Yan-hong, T., Yun-ke, Y., Li, W., Wang, X., Ma, J., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.004 · Cited by 82

Impact of age-related neuroglial cell responses on hippocampal deterioration

Ojo, J. O., Rezaie, P., Gabbott, P. L. A., & Stewart, M. G. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00057 · Cited by 83

Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease

Macchi, B., Paola, R. D., Marino‐Merlo, F., Felice, M. R., Cuzzocrea, S., & Mastino, A. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150225124928 · Cited by 80

Prevention of progression in Parkinson’s disease

Aaseth, J., Dušek, P., & Roos, P. M. (2018) · BioMetals · doi:10.1007/s10534-018-0131-5 · Cited by 83

Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson's disease

Rajan, S., Tryphena, K. P., Khan, S. S., Vora, L. K., Srivastava, S., Singh, S. B., & Khatri, D. K. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101915 · Cited by 84

Transient exposure to rotenone causes degeneration and progressive parkinsonian motor deficits, neuroinflammation, and synucleinopathy

Laar, A. D. V., Webb, K. R., Keeney, M. T., Laar, V. S. V., Zharikov, A., Burton, E. A., Hastings, T. G., Glajch, K. E., Hirst, W. D., Greenamyre, J. T., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00561-6 · Cited by 81

Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease

Funk, N., Wieghofer, P., Grimm, S., Schäfer, R., Bühring, H., Gasser, T., & Biskup, S. (2013) · Movement Disorders · doi:10.1002/mds.25300 · Cited by 81

Novel investigational adenosine A2Areceptor antagonists for Parkinson's disease

Pinna, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903241615 · Cited by 81

Inhibitory action of minocycline on lipopolysaccharide-lnduced release of nitric oxide and prostaglandin E2 in BV2 microglial cells

Kim, S., Kong, P., Kim, B.-S., Sheen, D., Nam, S.-Y., & Chun, W. (2004) · Archives of Pharmacal Research · doi:10.1007/bf02980066 · Cited by 81

Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration

Wang, X., Chen, S., Ma, G., Ye, M., & Lü, G. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.06.012 · Cited by 81

Microglial activation and cell death induced by the mitochondrial toxin 3-nitropropionic acid: in vitro and in vivo studies

Ryu, J. K., Nagai, A., Kim, J., Lee, M. C., McLarnon, J. G., & Kim, S. U. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00002-0 · Cited by 81

Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system

Ismaiel, A. A., Espinosa‐Oliva, A. M., Santiago, M., García-Quintanilla, A., Oliva-Martín, M. J., Herrera, A. J., Venero, J. L., & de Pablos, R. M. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.03.004 · Cited by 81

Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases

Madeira, M. H., Boia, R., Ambrósio, A. F., & Santiago, A. R. (2017) · Mediators of Inflammation · doi:10.1155/2017/4761081 · Cited by 87

Etiology of Parkinson's Disease

Huang, Z., de la Fuente‐Fernández, R., & Stoessl, A. J. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000319x · Cited by 81

Abnormal hippocampal neurogenesis in Parkinson’s disease: relevance to a new therapeutic target for depression with Parkinson’s disease

Lim, J., Bang, Y., & Choi, H. J. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1063-x · Cited by 82

The Endotoxin Hypothesis of Parkinson's Disease

Brown, G. C., Camacho, M., & Williams‐Gray, C. H. (2023) · Movement Disorders · doi:10.1002/mds.29432 · Cited by 85

Up-regulation of major histocompatibility complex class II antigen expression in the central nervous system of dogs with spontaneous canine distemper virus encephalitis

Alldinger, S., Wünschmann, A., Baumgärtner, W., Voß, C., & Kremmer, E. (1996) · Acta Neuropathologica · doi:10.1007/s004010050518 · Cited by 80

Studying neurodegenerative diseases in culture models

Schlachetzki, J. C. M., Saliba, S. W., & de Oliveira, A. C. P. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1159 · Cited by 85

Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson’s disease: Role of regulatory T cells

Chung, E. S., Kim, H., Lee, G., Park, S., Kim, H., & Bae, H. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.08.013 · Cited by 79

Manganese potentiates nitric oxide production by microglia

Chang, J. Y., & Liu, L.-Z. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00082-0 · Cited by 80

Complex Deregulation and Expression of Cytokines and Mediators of the Immune Response in P arkinson's Disease Brain is Region Dependent

Garcia‐Esparcia, P., Llorens, F., Carmona, M., & Ferrer, I. (2014) · Brain Pathology · doi:10.1111/bpa.12137 · Cited by 80

Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease

L’Episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Morale, M. C., Serapide, M. F., Pluchino, S., & Marchetti, B. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt053 · Cited by 83

A Decade of Research on TLR2 Discovering Its Pivotal Role in Glial Activation and Neuroinflammation in Neurodegenerative Diseases

Hayward, J. H., & Lee, S. J. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.2.138 · Cited by 82

Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?

Bisaglia, M., Filograna, R., Beltramini, M., & Bubacco, L. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2013.12.009 · Cited by 81

Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease

Thome, A. D., Atassi, F., Wang, J., Faridar, A., Zhao, W., Thonhoff, J. R., Beers, D. R., Lai, E. C., & Appel, S. H. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00188-5 · Cited by 80

Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease

Cardinale, A., Calabrese, V., de Iure, A., & Picconi, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126517 · Cited by 79

Oxidative stress and Parkinson's disease

Jenner, P. G. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83024-7 · Cited by 79

Expression of the histocompatibility glycoprotein HLA-DR in neurological disease

McGeer, P. L., Itagaki, S., & McGeer, E. G. (1988) · Acta Neuropathologica · doi:10.1007/bf00689592 · Cited by 420

HLA-DR reactive microglia in Parkinson's disease

Itagaki, S., McGeer, P. L., & McGeer, E. G. (1987) · Journal of Neuroimmunology · doi:10.1016/0165-5728(87)90252-9 · Cited by 5

Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR

McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791

Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain

Styren, S. D., Civin, W. H., & Rogers, J. (1990) · Experimental Neurology · doi:10.1016/0014-4886(90)90054-v · Cited by 191